Navigation Links
Advanced Life Sciences to Participate in Antibiotics Expert Panel at the 10th Annual BIO CEO & Investor Conference
Date:2/4/2008

- Corporate Presentation to be Webcast -

CHICAGO, Feb. 4 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases, today announced that its Chairman and CEO, Dr. Michael Flavin will participate in the "Antibiotics: Super Drugs Against Super Bugs" panel at the BIO CEO and Investor Conference 2008 on Wednesday, February 13, 2008 at 9:30 AM ET at the Waldorf Astoria Hotel in New York City, NY.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)

In addition, Advanced Life Sciences management will make a corporate presentation to investors on Tuesday, February 12 at 11:00 AM ET. The Company's presentation will be delivered in The New Amsterdam Suite at The Waldorf Astoria Hotel in New York City, NY. The webcast can be accessed through the Investor Relations page on the Advanced Life Sciences website, http://www.advancedlifesciences.com. Those interested in listening to the presentation should log on a few minutes in advance in order to download any software or complete any sign-in that may be required.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections such as community acquired pneumonia (CAP). In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post- exposure, but the drug is not yet approved for this or any other indication. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
3. Advanced Age No Bar to Liver Transplant
4. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
5. Advanced technologies aim to transform the coaching of top athletes
6. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
7. Advanced Life Sciences Joins NASDAQ Capital Market
8. Experimental drug shows promise in advanced kidney cancer
9. TCS Healthcare Technologies Announces Full Integration of Case Management Adherence Guidelines into Acuity Advanced Care(TM) System
10. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... ... Academy of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) ... a live webinar designed to help nutrition educators and students inform consumers about ...
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has ... of more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers ... and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box ...
(Date:3/29/2017)... ... ... is the main cause of hay fever in the United States, with an estimated 95 ... May to July each year; with the worst time for sufferers being June and July. ... http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent studies ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... ... 29, 2017 , ... Based on research from Guardian’s Fourth ... in trying to balance both short-term and long-term benefits demands. Are employers ... growing complexity, companies are finding that the short-term strategies used to control costs, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Bodycad announced today ... Administration (FDA) 510(k) clearance for its Bodycad Unicompartmental ... truly personalized orthopaedic restoration. Bodycad is the first ... joint reconstruction implant system. Bodycad,s ... personalized restoration of the patient,s unique anatomical features ...
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a clinical ... through treatment, today announced that Carmine N. Stengone , president ... at the Needham & Company 16 th Annual Healthcare Conference ... PDT) at the Westin Grand Central Hotel in New ... ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets ... Market 2014 - 2025" report to their offering. ... The ... 303.7 million by 2025. Increasing geriatric population prone to orthopedic ... orthopedic navigation systems over the forecast period. Osteoarthritis and osteoporosis ...
Breaking Medicine Technology: